Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Sattva S. Neelapu; Caron A. Jacobson; Olalekan O. Oluwole; Javier Munoz; Abhinav Deol; David B. Miklos; Nancy L. Bartlett; Ira Braunschweig; Yizhou Jiang; Jenny J. Kim; Lianqing Zheng; John M. Rossi; Frederick L. Locke

doi:10.1182/BLOOD.2019004162

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Sattva S. Neelapu, Caron A. Jacobson, Olalekan O. Oluwole, Javier Munoz, Abhinav Deol, David B. Miklos, Nancy L. Bartlett, Ira Braunschweig, Yizhou Jiang, Jenny J. Kim, Lianqing Zheng, John M. Rossi, Frederick L. Locke

Medicine

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	2106-2109
Number of pages	4
Journal	Blood
Volume	135
Issue number	23
DOIs	https://doi.org/10.1182/BLOOD.2019004162
State	Published - Jun 4 2020

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/BLOOD.2019004162

Cite this

Neelapu, S. S., Jacobson, C. A., Oluwole, O. O., Munoz, J., Deol, A., Miklos, D. B., Bartlett, N. L., Braunschweig, I., Jiang, Y., Kim, J. J., Zheng, L., Rossi, J. M., & Locke, F. L. (2020). Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood, 135(23), 2106-2109. https://doi.org/10.1182/BLOOD.2019004162

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. / Neelapu, Sattva S.; Jacobson, Caron A.; Oluwole, Olalekan O.; Munoz, Javier; Deol, Abhinav; Miklos, David B.; Bartlett, Nancy L.; Braunschweig, Ira; Jiang, Yizhou; Kim, Jenny J.; Zheng, Lianqing; Rossi, John M.; Locke, Frederick L.

In: Blood, Vol. 135, No. 23, 04.06.2020, p. 2106-2109.

Research output: Contribution to journal › Letter › peer-review

Neelapu, Sattva S. ; Jacobson, Caron A. ; Oluwole, Olalekan O. ; Munoz, Javier ; Deol, Abhinav ; Miklos, David B. ; Bartlett, Nancy L. ; Braunschweig, Ira ; Jiang, Yizhou ; Kim, Jenny J. ; Zheng, Lianqing ; Rossi, John M. ; Locke, Frederick L. / Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. In: Blood. 2020 ; Vol. 135, No. 23. pp. 2106-2109.

@article{303cb197416b436d9750c012c463eb0d,

title = "Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma",

author = "Neelapu, {Sattva S.} and Jacobson, {Caron A.} and Oluwole, {Olalekan O.} and Javier Munoz and Abhinav Deol and Miklos, {David B.} and Bartlett, {Nancy L.} and Ira Braunschweig and Yizhou Jiang and Kim, {Jenny J.} and Lianqing Zheng and Rossi, {John M.} and Locke, {Frederick L.}",

note = "Funding Information: This work was supported by Kite, a Gilead Company, and the Leukemia and Lymphoma Society Therapy Acceleration Program. Medical writing support was provided by Jennifer Leslie, of Nexus Global Group Science, with funding from Kite. Funding Information: Conflict-of-interest disclosure: S.S.N. has received personal fees from Kite, Merck, Novartis, Celgene, Pfizer, Allogene, Cell Medica, Incyte, Precision Biosciences, Legend Biotech, and Unum Therapeutics and research support from Kite, Bristol-Myers Squibb, Merck, Poseida, Cel-lectis, Celgene, Karus Therapeutics, Unum Therapeutics, Allogene, and Acerta. C.A.J. has received personal fees from Kite, Novartis, Precision Bioscience, Bayer, Pfizer, and Humanigen. J.M. has served in a consultancy or advisory role for Genentech, Alexion, Bayer, Bristol-Myers Squibb, Juno/Celgene, Kite, Kyowa, Merck, Pfizer, Pharmacyclics/ Janssen, and Seattle Genetics; has served on speakers{\textquoteright} bureaus for AstraZeneca, Bayer, Fosunkite, Genentech, Kite, Kyowa, Pharmacyclics/ Janssen, and Seattle Genetics; and has received research funding from Celgene, Genentech, Incyte, Janssen, Kite, Pharmacyclics, Portola, and Seattle Genetics. A.D. has served on advisory boards for Kite, Agios, and Novartis and has received research funding from Bristol-Myers Squibb. D.B.M has received grants and research funding from and served on a scientific advisory board for Kite. N.L.B has received research funding from Affimed, Bristol-Myers Squibb, Celgene, Forty Seven, Genentech, Gilead, Immune Design, Kite, Merck, Millennium, and Pharmacyclics and serves on advisory boards for Acerta and ADC Therapeutics. I.B. has received speaker fees from Kite. Y.J., J.J.K., L.Z., and J.M.R. are employees of Kite and have equity ownership in Gilead Sciences Inc. F.L.L has been a scientific advisor to Kite, Novartis, and GammaDelta Therapeutics and is a consultant for Cellular Biomedicine Group Inc. The remaining authors declare no competing financial interests.",

year = "2020",

month = jun,

day = "4",

doi = "10.1182/BLOOD.2019004162",

language = "English (US)",

volume = "135",

pages = "2106--2109",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "23",

}

TY - JOUR

T1 - Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

AU - Neelapu, Sattva S.

AU - Jacobson, Caron A.

AU - Oluwole, Olalekan O.

AU - Munoz, Javier

AU - Deol, Abhinav

AU - Miklos, David B.

AU - Bartlett, Nancy L.

AU - Braunschweig, Ira

AU - Jiang, Yizhou

AU - Kim, Jenny J.

AU - Zheng, Lianqing

AU - Rossi, John M.

AU - Locke, Frederick L.

N1 - Funding Information: This work was supported by Kite, a Gilead Company, and the Leukemia and Lymphoma Society Therapy Acceleration Program. Medical writing support was provided by Jennifer Leslie, of Nexus Global Group Science, with funding from Kite. Funding Information: Conflict-of-interest disclosure: S.S.N. has received personal fees from Kite, Merck, Novartis, Celgene, Pfizer, Allogene, Cell Medica, Incyte, Precision Biosciences, Legend Biotech, and Unum Therapeutics and research support from Kite, Bristol-Myers Squibb, Merck, Poseida, Cel-lectis, Celgene, Karus Therapeutics, Unum Therapeutics, Allogene, and Acerta. C.A.J. has received personal fees from Kite, Novartis, Precision Bioscience, Bayer, Pfizer, and Humanigen. J.M. has served in a consultancy or advisory role for Genentech, Alexion, Bayer, Bristol-Myers Squibb, Juno/Celgene, Kite, Kyowa, Merck, Pfizer, Pharmacyclics/ Janssen, and Seattle Genetics; has served on speakers’ bureaus for AstraZeneca, Bayer, Fosunkite, Genentech, Kite, Kyowa, Pharmacyclics/ Janssen, and Seattle Genetics; and has received research funding from Celgene, Genentech, Incyte, Janssen, Kite, Pharmacyclics, Portola, and Seattle Genetics. A.D. has served on advisory boards for Kite, Agios, and Novartis and has received research funding from Bristol-Myers Squibb. D.B.M has received grants and research funding from and served on a scientific advisory board for Kite. N.L.B has received research funding from Affimed, Bristol-Myers Squibb, Celgene, Forty Seven, Genentech, Gilead, Immune Design, Kite, Merck, Millennium, and Pharmacyclics and serves on advisory boards for Acerta and ADC Therapeutics. I.B. has received speaker fees from Kite. Y.J., J.J.K., L.Z., and J.M.R. are employees of Kite and have equity ownership in Gilead Sciences Inc. F.L.L has been a scientific advisor to Kite, Novartis, and GammaDelta Therapeutics and is a consultant for Cellular Biomedicine Group Inc. The remaining authors declare no competing financial interests.

PY - 2020/6/4

Y1 - 2020/6/4

UR - http://www.scopus.com/inward/record.url?scp=85085664138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085664138&partnerID=8YFLogxK

U2 - 10.1182/BLOOD.2019004162

DO - 10.1182/BLOOD.2019004162

M3 - Letter

C2 - 32181801

AN - SCOPUS:85085664138

VL - 135

SP - 2106

EP - 2109

JO - Blood

JF - Blood

SN - 0006-4971

IS - 23

ER -